-
1
-
-
0028500187
-
The activation of phosphatidylinositol 3-kinase by Ras
-
Kodaki T, Woscholski R, Hallberg B, Rodriguez-Viciana P, Downward J, Parker PJ. The activation of phosphatidylinositol 3-kinase by Ras. Curr Biol. 1994;4(9):798-806.
-
(1994)
Curr Biol.
, vol.4
, Issue.9
, pp. 798-806
-
-
Kodaki, T.1
Woscholski, R.2
Hallberg, B.3
Rodriguez-Viciana, P.4
Downward, J.5
Parker, P.J.6
-
2
-
-
0028074316
-
Phosphatidylinositol-3-OH kinase as a direct target of Ras
-
Rodriguez-Viciana P, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature. 1994;370(6490):527-532.
-
(1994)
Nature
, vol.370
, Issue.6490
, pp. 527-532
-
-
Rodriguez-Viciana, P.1
-
3
-
-
0030911052
-
Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras
-
Rodriguez-Viciana P, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell. 1997;89(3):457-467.
-
(1997)
Cell
, vol.89
, Issue.3
, pp. 457-467
-
-
Rodriguez-Viciana, P.1
-
4
-
-
0029990003
-
Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation
-
Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, Waterfield MD, Downward J. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J. 1996;15(10):2442-2451.
-
(1996)
EMBO J.
, vol.15
, Issue.10
, pp. 2442-2451
-
-
Rodriguez-Viciana, P.1
Warne, P.H.2
Vanhaesebroeck, B.3
Waterfield, M.D.4
Downward, J.5
-
5
-
-
34249026448
-
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice
-
Gupta S, et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell. 2007;129(5):957-968.
-
(2007)
Cell
, vol.129
, Issue.5
, pp. 957-968
-
-
Gupta, S.1
-
6
-
-
84887532497
-
Requirement for interaction of PI 3-kinase p110α with RAS in lung tumor maintenance
-
Castellano E, et al. Requirement for interaction of PI 3-kinase p110α with RAS in lung tumor maintenance. Cancer Cell. 2013;24(5):617-630.
-
(2013)
Cancer Cell.
, vol.24
, Issue.5
, pp. 617-630
-
-
Castellano, E.1
-
7
-
-
84874650275
-
Development of PI3K inhibitors: Lessons learned from early clinical trials
-
Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143-153.
-
(2013)
Nat Rev Clin Oncol.
, vol.10
, Issue.3
, pp. 143-153
-
-
Rodon, J.1
Dienstmann, R.2
Serra, V.3
Tabernero, J.4
-
8
-
-
84873360893
-
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
-
Mao M, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013;19(3):657-667.
-
(2013)
Clin Cancer Res.
, vol.19
, Issue.3
, pp. 657-667
-
-
Mao, M.1
-
9
-
-
84866930352
-
Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models
-
Roberts PJ, et al. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res. 2012;18(19):5290-5303.
-
(2012)
Clin Cancer Res.
, vol.18
, Issue.19
, pp. 5290-5303
-
-
Roberts, P.J.1
-
10
-
-
78650008177
-
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K
-
Villanueva J, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18(6):683-695.
-
(2010)
Cancer Cell.
, vol.18
, Issue.6
, pp. 683-695
-
-
Villanueva, J.1
-
11
-
-
0037264633
-
Targeting RAS signalling pathways in cancer therapy
-
Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11-22.
-
(2003)
Nat Rev Cancer
, vol.3
, Issue.1
, pp. 11-22
-
-
Downward, J.1
-
14
-
-
58149345546
-
Co-evolution of tumor cells and their microenvironment
-
Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009;25(1):30-38.
-
(2009)
Trends Genet.
, vol.25
, Issue.1
, pp. 30-38
-
-
Polyak, K.1
Haviv, I.2
Campbell, I.G.3
-
15
-
-
33645739790
-
Tumor stroma and regulation of cancer development
-
Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006;1:119-150.
-
(2006)
Annu Rev Pathol.
, vol.1
, pp. 119-150
-
-
Tlsty, T.D.1
Coussens, L.M.2
-
16
-
-
85013312416
-
Tumor angiogenesis: Therapeutic implications
-
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-1186.
-
(1971)
N Engl J Med.
, vol.285
, Issue.21
, pp. 1182-1186
-
-
Folkman, J.1
-
18
-
-
33750826279
-
The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation
-
Zhao JJ, et al. The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A. 2006;103(44):16296-16300.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, Issue.44
, pp. 16296-16300
-
-
Zhao, J.J.1
-
19
-
-
0033574429
-
Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase
-
Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase. J Biol Chem. 1999;274(16):10963-10968.
-
(1999)
J Biol Chem.
, vol.274
, Issue.16
, pp. 10963-10968
-
-
Bi, L.1
Okabe, I.2
Bernard, D.J.3
Wynshaw-Boris, A.4
Nussbaum, R.L.5
-
20
-
-
0038363443
-
Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2
-
Cao R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med. 2003;9(5):604-613.
-
(2003)
Nat Med.
, vol.9
, Issue.5
, pp. 604-613
-
-
Cao, R.1
-
21
-
-
84869777544
-
+ regulatory T cells impairs mouse melanoma growth
-
+ regulatory T cells impairs mouse melanoma growth. J Exp Med. 2012;209(11):2001-2016.
-
(2012)
J Exp Med.
, vol.209
, Issue.11
, pp. 2001-2016
-
-
Hansen, W.1
-
22
-
-
84860366086
-
Antiangiogenic therapy - Evolving view based on clinical trial results
-
Jayson GC, Hicklin DJ, Ellis LM. Antiangiogenic therapy - evolving view based on clinical trial results. Nat Rev Clin Oncol. 2012;9(5):297-303.
-
(2012)
Nat Rev Clin Oncol.
, vol.9
, Issue.5
, pp. 297-303
-
-
Jayson, G.C.1
Hicklin, D.J.2
Ellis, L.M.3
-
23
-
-
67649909568
-
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma
-
Hauschild A, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009;27(17):2823-2830.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.17
, pp. 2823-2830
-
-
Hauschild, A.1
-
24
-
-
77955887676
-
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303)
-
Kindler HL, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28(22):3617-3622.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.22
, pp. 3617-3622
-
-
Kindler, H.L.1
-
25
-
-
65549150854
-
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
-
Van Cutsem E, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27(13):2231-2237.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.13
, pp. 2231-2237
-
-
Van Cutsem, E.1
-
26
-
-
84861690508
-
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401
-
Kelly WK, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30(13):1534-1540.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.13
, pp. 1534-1540
-
-
Kelly, W.K.1
-
27
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
Sandler A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-2550.
-
(2006)
N Engl J Med.
, vol.355
, Issue.24
, pp. 2542-2550
-
-
Sandler, A.1
-
28
-
-
77951639655
-
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer
-
Scagliotti G, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(11):1835-1842.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.11
, pp. 1835-1842
-
-
Scagliotti, G.1
-
29
-
-
84863936062
-
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial
-
Scagliotti GV, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol. 2012;30(17):2070-2078.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.17
, pp. 2070-2078
-
-
Scagliotti, G.V.1
-
30
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335- 2342.
-
(2004)
N Engl J Med.
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
-
31
-
-
84856253589
-
Bevacizumab added to neoadjuvant chemotherapy for breast cancer
-
Bear HD, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012;366(4):310-320.
-
(2012)
N Engl J Med.
, vol.366
, Issue.4
, pp. 310-320
-
-
Bear, H.D.1
-
32
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
Miller K, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-2676.
-
(2007)
N Engl J Med.
, vol.357
, Issue.26
, pp. 2666-2676
-
-
Miller, K.1
-
33
-
-
79953874259
-
RIBBON-1: Randomized, doubleblind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
-
Robert NJ, et al. RIBBON-1: randomized, doubleblind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29(10):1252-1260.
-
(2011)
J Clin Oncol.
, vol.29
, Issue.10
, pp. 1252-1260
-
-
Robert, N.J.1
-
34
-
-
84856291930
-
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
-
von Minckwitz G, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366(4):299-309.
-
(2012)
N Engl J Med.
, vol.366
, Issue.4
, pp. 299-309
-
-
Von Minckwitz, G.1
-
35
-
-
84855161152
-
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: A meta-analysis
-
Cortes J, et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann OncolAnn Oncol. 2012;23(5):1130-1137.
-
(2012)
Ann OncolAnn Oncol.
, vol.23
, Issue.5
, pp. 1130-1137
-
-
Cortes, J.1
-
36
-
-
79551520348
-
Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis
-
Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. J Am Med Assoc. 2011;305(5):487-494.
-
(2011)
J Am Med Assoc.
, vol.305
, Issue.5
, pp. 487-494
-
-
Ranpura, V.1
Hapani, S.2
Wu, S.3
-
37
-
-
79957773120
-
Tumor necrosis as a prognostic factor for stage IA non-small cell lung cancer
-
Park SY, Lee H-S, Jang H-J, Lee GK, Chung KY, Zo JI. Tumor necrosis as a prognostic factor for stage IA non-small cell lung cancer. Ann Thoracic Surg. 2011;91(6):1668-1673.
-
(2011)
Ann Thoracic Surg.
, vol.91
, Issue.6
, pp. 1668-1673
-
-
Park, S.Y.1
Lee, H.-S.2
Jang, H.-J.3
Lee, G.K.4
Chung, K.Y.5
Zo, J.I.6
-
38
-
-
44349119736
-
Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration
-
Graupera M, et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature. 2008;453(7195):662-666.
-
(2008)
Nature
, vol.453
, Issue.7195
, pp. 662-666
-
-
Graupera, M.1
-
39
-
-
51349169062
-
K-ras/PI3K-Akt signaling is essential for zebrafish hematopoiesis and angiogenesis
-
Liu L, Zhu S, Gong Z, Low BC. K-ras/PI3K-Akt signaling is essential for zebrafish hematopoiesis and angiogenesis. PLoS One. 2008;3(8):e2850.
-
(2008)
PLoS One
, vol.3
, Issue.8
-
-
Liu, L.1
Zhu, S.2
Gong, Z.3
Low, B.C.4
-
40
-
-
84885440456
-
Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis
-
Soler A, et al. Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. J Exp Med. 2013;210(10):1937-1945.
-
(2013)
J Exp Med.
, vol.210
, Issue.10
, pp. 1937-1945
-
-
Soler, A.1
-
41
-
-
80053493427
-
Beyond VEGF: Inhibition of the fibroblast growth factor pathway and antiangiogenesis
-
Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res. 2011;17(19):6130-6139.
-
(2011)
Clin Cancer Res.
, vol.17
, Issue.19
, pp. 6130-6139
-
-
Lieu, C.1
Heymach, J.2
Overman, M.3
Tran, H.4
Kopetz, S.5
-
42
-
-
0037906432
-
Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis
-
Giavazzi R, et al. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol. 2003;162(6):1913-1926.
-
(2003)
Am J Pathol.
, vol.162
, Issue.6
, pp. 1913-1926
-
-
Giavazzi, R.1
-
43
-
-
0027053487
-
Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro
-
Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun. 1992;189(2):824-831.
-
(1992)
Biochem Biophys Res Commun.
, vol.189
, Issue.2
, pp. 824-831
-
-
Pepper, M.S.1
Ferrara, N.2
Orci, L.3
Montesano, R.4
-
44
-
-
84866856702
-
Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis
-
Cao R, et al. Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc Natl Acad Sci U S A. 2012;109(39):15894- 15899.
-
(2012)
Proc Natl Acad Sci U S A
, vol.109
, Issue.39
, pp. 15894-15899
-
-
Cao, R.1
-
45
-
-
84857008164
-
Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma
-
Finn RS, et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18(7):2090-2098.
-
(2012)
Clin Cancer Res.
, vol.18
, Issue.7
, pp. 2090-2098
-
-
Finn, R.S.1
-
46
-
-
84864955678
-
A phase I, open-label doseescalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer
-
Doebele RC, et al. A phase I, open-label doseescalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2012;23(8):2094-2102.
-
(2012)
Ann Oncol.
, vol.23
, Issue.8
, pp. 2094-2102
-
-
Doebele, R.C.1
-
47
-
-
84886434204
-
Modulation of macrophage phenotype by cell shape
-
McWhorter FY, Wang T, Nguyen P, Chung T, Liu WF. Modulation of macrophage phenotype by cell shape. Proc Natl Acad Sci U S A. 2013;110(43):17253-17258.
-
(2013)
Proc Natl Acad Sci U S A
, vol.110
, Issue.43
, pp. 17253-17258
-
-
McWhorter, F.Y.1
Wang, T.2
Nguyen, P.3
Chung, T.4
Liu, W.F.5
-
48
-
-
67749101418
-
IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions
-
Airoldi I, et al. IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions. PLoS One. 2009;4(7):e6119.
-
(2009)
PLoS One
, vol.4
, Issue.7
-
-
Airoldi, I.1
-
49
-
-
0035869599
-
IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyteendothelial cell cross-talk
-
Strasly M, et al. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyteendothelial cell cross-talk. J Immunol. 2001;166(6):3890-3899.
-
(2001)
J Immunol.
, vol.166
, Issue.6
, pp. 3890-3899
-
-
Strasly, M.1
-
50
-
-
80355131976
-
Protective and pathogenic functions of macrophage subsets
-
Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723-737.
-
(2011)
Nat Rev Immunol.
, vol.11
, Issue.11
, pp. 723-737
-
-
Murray, P.J.1
Wynn, T.A.2
-
51
-
-
34248172324
-
Altered macrophage differentiation and immune dysfunction in tumor development
-
Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007;117(5):1155-1166.
-
(2007)
J Clin Invest.
, vol.117
, Issue.5
, pp. 1155-1166
-
-
Sica, A.1
Bronte, V.2
|